PEG IFN-alpha2a (Pegasys) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia).

Trial Profile

PEG IFN-alpha2a (Pegasys) Therapy in Patients With Chronic Myeloproliferative Diseases (Excluding Philadelphia Chromosome Positive Chronic Myeloid Leukemia).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 05 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
    • 13 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top